OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 (860) 240-0200
http://www.cga.ct.gov/ofa
sSB-1355
AN ACT CONCERNING PRESCRIPTION DRUGS, DEVICES AND
NONLEGEND DRUGS.
Primary Analyst: ME 4/8/25
Contributing Analyst(s): NB, BP, RP
Reviewer: PR
OFA Fiscal Note
State Impact:
Agency Affected Fund-Effect FY 26 $ FY 27 $
Resources of the General Fund GF - Revenue
Impact
See Below See Below
Note: GF=General Fund
Municipal Impact: None
Explanation
The bill makes various changes regarding prescription drugs
resulting in the impact described below.
Section 1 requires the Department of Consumer Protection (DCP) to
adopt regulations regarding nonsterile compounding pharmacies
resulting in no fiscal impact to the state.
1
Sections 4-12 prohibit manufacturing, selling, or dispensing a drug
while knowing that the drug will be used to execute a death sentence
and make certain violations subject to a civil penalty of up to $1,000 or
a fine of up to $500 resulting in a potential revenue gain to the state to
the extent violations occur.
Sections 13-14 exclude certain people from having to obtain a permit
1
While there is no cost to DCP to write the regulations, the regulations may result in a
cost depending on the language in the regulations and if they are approved by the
committee. 2025SB-01355-R000608-FN.DOCX Page 2 of 2
to sell nonlegend drugs from DCP resulting in a potential revenue loss
to the General Fund to the extent fewer permits are applied for. In FY
24 there were over 2,000 nonlegend drug permit applications and
renewal requests. The application fee for a nonlegend drug permit is
$140 and the renewal fee is $100.
The Out Years
The annualized ongoing fiscal impact identified above would
continue into the future subject to the number of violations, the number
of permits applied for, and inflation.